Manufacturers announce termination of Phase III study of elafibranor for non-alcoholic steatohepatitis (NASH) with fibrosis

In an interim analysis, elafibranor failed to meet its primary endpoint. The company reviewed the data and concluded it was unlikely to provide results that would be sufficient to support elafibranor for registration in NASH in the USA and Europe.